Glenmark Pharmaceuticals Q3 Results: Glenmark Pharmaceuticals posted a net profit of ₹348 crore in Q3 FY25, reversing a ₹351 crore loss YoY. Revenue surged 35% to ₹3,388 crore, with strong growth in ...

Glenmark Pharmaceuticals Ltd share price was up by 0.40% from the previous closing price of ₹1,373.80. Who are peers of Glenmark Pharmaceuticals Ltd? The peers of Glenmark Pharmaceuticals Ltd ...

Glenmark Pharmaceuticals and Ireland-based Cosmo Pharmaceuticals NV have received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to market a product for the treatment of ...

Glenmark Pharmaceuticals' subsidiary has introduced Latanoprost ophthalmic solution, a generic medication for glaucoma, in the US market. The product matches Upjohn US LLC's Xalatan Ophthalmic ...

Glenmark Pharmaceuticals Inc., USA announced today the launch of Latanoprost Ophthalmic Solution, 0.005 per cent, a generic version of Upjohn’s Xalatan. This marks the company’s fourth ...

Launched two decades ago, Glenmark’s Telma brand containing Telmisartan has become a household name for treating hypertension, heart failure, prevention of heart attack and stroke. According to ...

Glenmark Pharmaceuticals and Ireland-based Cosmo Pharmaceuticals NV have received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to market a product for the treatment of ...

According to IQVIA, sales data for the 12-month period ending December 2024, the Xalatan Ophthalmic Solution achieved annual sales of around USD 113.5 million. Glenmark Pharmaceuticals on Friday ...

Glenmark Pharmaceuticals Q3 Results 2025:Glenmark Pharmaceuticals declared their Q3 results on 14 Feb, 2025, revealing a significant increase in topline by 35.14%, with profit reaching ₹347.96 ...

Glenmark Pharmaceuticals on Wednesday, February 12, said its US-based subsidiary launched Clindamycin Phosphate Foam, which is used for the treatment of acne. This new product is bioequivalent and ...

Feb 14 (Reuters) - India's Glenmark Pharmaceuticals (GLEN.NS), opens new tab reported third-quarter profit below estimates on Friday due to bleak U.S. demand for its long-term illness drugs.

1 Glenmark’s Clindamycin Phosphate Foam, 1% is only approved for the indication(s) listed in Glenmark’s approved label. 2 All brand names and trademarks are the property of their respective owners. 3 ...